Ardana PLC
28 February 2008
Ardana plc
VOTING RIGHTS AND CAPITAL
Edinburgh, UK, February 28, 2008: Ardana plc (LSE:ARA), in conformity with the
Transparency Directive's transitional provision 6, today notifies the market of
the following:
As at 28 February 2008, the issued share capital and voting rights of Ardana plc
are as follows:
Ardana plc's capital consists of 65,511,729 ordinary 1p shares with voting
rights attached of one vote per ordinary share of which 12,681 ordinary shares
are held in Treasury.
Therefore, the total number of voting rights in Ardana plc is 65,499,048.
The above figure (65,499,048) may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Ardana plc under the FSA's
Disclosure and Transparency Rules.
For more information contact:
Ardana plc Financial Dynamics
Dr. Huw Jones. Chief Executive Officer Julia Phillips
Tel: + 44 (0) 131 226 8550 Emma Thompson
Tel: +44 (0)20 7831 3113
Ardana plc (LSE: ARA) is an emerging pharmaceutical company focused on the
discovery, development and marketing of innovative products to improve human
reproductive health, a $25.5 billion market.
Ardana's lead products are summarised below:
• Teverelix LA, in development for three initial indications (prostate
cancer, benign prostatic hyperplasia and endometriosis);
• ARD-0705 a growth hormone secretagogue in Phase III for the diagnosis of
growth hormone deficiency in adults;
• Testosterone Cream, a transdermal testosterone delivery system in
development for the treatment of male hypogonadism, in Phase III trials;
• Emselex(R), a once a day treatment for the symptoms of overactive bladder
syndrome, which Ardana has exclusive UK marketing and promotion rights and
is being distributed in collaboration with Novartis UK Limited;
• StriantTM SR, a testosterone replacement therapy that has been launched by
Ardana through its own sales force in the UK and through marketing partners
in certain European countries, as a treatment for men with confirmed
hypogonadism; and
• InvicorpTM, an injectable combination drug treatment for erectile
dysfunction, for which Ardana has marketing and manufacturing rights in
Europe and has been launched in Denmark.
For further information please see www.ardana.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange